[Does multiple myeloma response to induction therapy depend on plasma cell IL6 receptor gene expression?]. / L'expression de l'IL6-r par les plasmocytes influe-t-elle la réponse au traitement d'induction au cours du myélome multiple ?
Tunis Med
; 91(5): 337-41, 2013 May.
Article
en Fr
| MEDLINE
| ID: mdl-23716328
ABSTRACT
BACKGROUND:
Interleukine 6 (IL-6) is the most important cytokine involved in malignant plasma cells growth and survival.AIM:
To analyse bone marrow plasma cells IL6 receptor gene expression in both multiple myeloma patients at diagnosis and healthy bone marrow donors.METHODS:
Clinical and biological patients' features and responses to Dexamethasone-Thalidomide induction therapy were gathered. 47 patients and 16 case controls were analyzed Bone marrow plasma cells were isolated; and IL6 receptor gene expression was quantified using Taqman quantitative PCr technology and 2-ΔCT formula.RESULTS:
Quantitative and qualitative IL6 receptor gene expression were negatively correlated with the degree of response to therapy (p= 0.02). In this study, plasma cells IL6 receptor gene expression seems to be decisive in predicting the response to treatment.CONCLUSION:
Understanding the mechanisms involved in plasma cells IL6 receptor gene expression may offer a better appreciation of the physiopathologic and anti-oncogenic ways of drug resistance in multiple myeloma and consequently the discovery of new specific drugs.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Células Plasmáticas
/
Receptores de Interleucina-6
/
Quimioterapia de Inducción
/
Mieloma Múltiple
Tipo de estudio:
Observational_studies
/
Qualitative_research
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Fr
Revista:
Tunis Med
Año:
2013
Tipo del documento:
Article